ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Opportunities in Tacrolimus Therapeutic Drug Monitoring

N. Jandovitz, J. Lee, S. Hammad, J. McKeen, S. Martin, D. Tsapepas.

Department of Pharmacy, NewYork-Presbyterian Hospital, NY.

Meeting: 2015 American Transplant Congress

Abstract number: C66

Keywords: Dosage, Kidney transplantation, Pharmacoeconomics, Pharmacokinetics

Session Information

Date: Monday, May 4, 2015

Session Name: Poster Session C: Immunosuppression/Compliance

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Harmonization of an LC-MS/MS Assay for Therapeutic Drug Monitoring of Tacrolimus
  • Assessment of Renal Function in Kidney Transplant Recipients Through Therapeutic Drug Monitoring of Vancomycin

Tacrolimus requires diligent therapeutic drug monitoring (TDM) to maintain appropriate serum concentrations after transplant. To optimize efficacy & minimize toxicity frequent levels are drawn, commonly on a daily basis for inpatients. This analysis identifies areas of improvement from current TDM practices to develop an efficacious & cost-effective tacrolimus dosing & TDM algorithm.

Single-center, retrospective study of 100 adult renal allograft recipients transplanted from Jan–Jun 2013. Information on tacrolimus dosing & serum trough levels were collected from the day of transplant to the day of hospital discharge or post-operative day 14. Monitoring practices were deemed appropriate if the level was obtained 0–30 min prior to a morning dose of tacrolimus once steady state was reached (2.5days of consistent dosing). A cost analysis was determined by comparing the difference of total tacrolimus levels drawn versus the number of levels appropriately obtained.

Demographics summarized in Table 1. During the study period 475 tacrolimus levels were drawn. Of these, 352 were deemed inappropriate for the following reasons: tacrolimus level not at steady state & level was drawn (n=333); medication at steady state & therapeutic & level was drawn (n=19). Mean inpatient length of stay was 6±3days. Liberal use of TDM had a significant cost burden, $12,000 on our institution. An algorithm to standardize & encourage appropriate tacrolimus lab draws was developed. If the algorithm was applied to our current cohort, this would lead to $9,000 in cost-savings.

We identified a high incidence of inappropriate TDM (74%) among our renal transplant recipients. Standardized TDM practices are necessary to provide optimal care & to ensure efficacy, safety, & cost-effectiveness. Prospective monitoring of the TDM algorithm for all transplant recipients at our center is ongoing.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Jandovitz N, Lee J, Hammad S, McKeen J, Martin S, Tsapepas D. Opportunities in Tacrolimus Therapeutic Drug Monitoring [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/opportunities-in-tacrolimus-therapeutic-drug-monitoring/. Accessed January 26, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.